Expression of Mismatch Repair Proteins Hmlh1, Hmsh2 and Hmsh6 in Sporadic Colorectal Cancer

Yu Pengfei,Fei Xiang,Wei Xueming,Li Ming,Gu Jin,Gu Guoli
DOI: https://doi.org/10.3877/cma.j.issn.1674-0793.2015.03.005
2015-01-01
Abstract:Objective To investigate the expression and clinical significance of mismatch repair proteins hMLH1, hMSH2 and hMSH6 in sporadic colorectal carcinoma (SCRC). Methods Two hundred and ninety patients with SCRC were studied, who underwent surgery in the Department of General Surgery, the Air Force General Hospital and the Department of Colorectal Surgery, Beijing Cancer Hospital from March 2008 to December 2012. Immunohistochemistry was used to detect hMLH1, hMSH2 and hMSH6 expression in tumor tissues. The relationship between expression and clinicopathological data was analyzed retrospectively. Results The absent expression rates of hMLH1, hMSH2 and hMSH6 only in tumor tis-sues were 13.4% (39/290), 12.1% (35/290) and 29.0% (84/290), respectively. The absent expression rates of hMLH1 and hMSH2, hMLH1 and hMSH6, hMSH2 and hMSH6, and hMLH1, hMSH2 and hMSH6 were 3.8% (11/290), 10.0% (29/290), 7.2% (21/290) and 3.4% (10/290), respectively. The absent expression rate of hMLH1 in highly differentiated adenocarcinoma tissues was obviously higher than that of moderatelyto poorly differentiated adenocarcinoma and mucous carcinomas tissues (P<0.01). In the tumor tissues less than 5 cm, the expression level of hMSH2 was obviously higher than that of more than 5 cm, so as hMSH6 (P<0.05). The expression rate of hMSH6 in female group was clearly higher than that of male group (P<0.01), and the expression rate of hMSH6 in high lymph node metastasis of tumor tissues was higher than that of low lymph node metastasis. Conclusions The absent expressions of hMLH1, hMSH2 and hMSH6 are common in SCRC, and the clinicopathological parameters of SCRC is obviously different from hereditary nonpolyposis colorectal cancer (HNPCC). Therefore, the biological effects, indicators for evaluation of degree of malignancy, individualized chemotherapy regimens and prognostic indicators may be different from those in HNPCC.
What problem does this paper attempt to address?